| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ikzf2 |
| Uniprot No | Q9UKS7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-500aa |
| 氨基酸序列 | METEAIDGYITCDNELSPEREHSNMAIDLTSSTPNGQHASPSHMTSTNSVKLEMQSDEECDRKPLSREDEIRGHDEGSSLEEPLIESSEVADNRKVQELQGEGGIRLPNGERPFHCNQCGASFTQKGNLLRHIKLHSGEKPFKCPFCSYACRRRDALTGHLRTHSVGKPHKCNYCGRSYKQRSSLEEHKERCHNYLQNVSMEAAGQVMSHHVPPMEDCKEQEPIMDNNISLVPFERPAVIEKLTGNMGKRKSSTPQKFVGEKLMRFSYPDIHFDMNLTYEKEAELMQSHMMDQAINNAITYLGAEALHPLMQHPPSTIAEVAPVISSAYSQVYHPNRIERPISRETADSHENNMDGPISLIRPKSRPQEREASPSNSCLDSTDSESSHDDHQSYQGHPALNPKRKQSPAYMKEDVKALDTTKAPKGSLKDIYKVFNGEGEQIRAFKCEHCRVLFLDHVMYTIHMGCHGYRDPLECNICGYRSQDRYEFSSHIVRGEHTFH |
| 预测分子量 | 59,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IKZF2重组蛋白的3篇参考文献示例(注：文献信息为示例性内容，可能不完全对应真实出版物)：
1. **文献名称**：*Structural and functional analysis of IKZF2 in T-cell development*
**作者**：Smith A, et al.
**摘要**：研究解析了IKZF2重组蛋白的锌指结构域，揭示其通过调控染色质重塑参与T细胞分化的分子机制。
2. **文献名称**：*IKZF2重组蛋白在急性髓系白血病中的异常表达及靶向策略*
**作者**：Zhang L, et al.
**摘要**：发现IKZF2重组蛋白在AML患者中高表达，并通过抑制其DNA结合活性可诱导白血病细胞凋亡。
3. **文献名称**：*IKZF2重组蛋白介导的免疫抑制微环境促进肿瘤转移*
**作者**：Wang Y, et al.
**摘要**：证实IKZF2重组蛋白通过调控PD-L1表达增强肿瘤免疫逃逸，提示其作为免疫治疗新靶点。
(注：实际文献需通过PubMed/Google Scholar等平台检索，建议结合具体研究方向筛选。)
IKZF2 (Ikaros Family Zinc Finger 2), also known as Helios, is a member of the Ikaros transcription factor family characterized by zinc finger domains critical for DNA binding and protein interactions. It plays a regulatory role in immune system development and function, particularly in lymphoid lineages. Structurally, IKZF2 contains N-terminal zinc fingers that mediate DNA binding and chromatin remodeling, while C-terminal regions facilitate homo- or heterodimerization with other Ikaros family members (e.g., IKZF1). This protein is predominantly expressed in regulatory T cells (Tregs), where it helps maintain immune tolerance and suppress excessive immune responses by modulating gene expression networks.
Recombinant IKZF2 protein is engineered in vitro using expression systems like E. coli or mammalian cells, often fused with tags (e.g., His-tag) for purification and detection. Its production enables functional studies of IKZF2's molecular mechanisms, including DNA-binding specificity, interaction partners, and post-translational modifications. Researchers utilize recombinant IKZF2 to investigate its role in T cell differentiation, autoimmune diseases, and cancer immunology, as dysregulated IKZF2 expression has been linked to conditions like leukemia, lymphoma, and immune dysregulation syndromes.
Recent studies highlight IKZF2's therapeutic potential. In cancer immunotherapy, modulating IKZF2 activity in Tregs may enhance anti-tumor immunity. Additionally, IKZF2 mutations are associated with primary immunodeficiency disorders, making the recombinant protein valuable for mechanistic studies and drug screening. However, functional redundancy within the Ikaros family and context-dependent regulatory effects necessitate careful interpretation of experimental results using recombinant IKZF2 constructs.
×
